|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: USPL1 |
Gene summary for USPL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | USPL1 | Gene ID | 10208 |
| Gene name | ubiquitin specific peptidase like 1 | |
| Gene Alias | C13orf22 | |
| Cytomap | 13q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8K1B1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10208 | USPL1 | LZE4T | Human | Esophagus | ESCC | 2.65e-09 | 5.93e-01 | 0.0811 |
| 10208 | USPL1 | LZE24T | Human | Esophagus | ESCC | 6.41e-15 | 1.47e-01 | 0.0596 |
| 10208 | USPL1 | P1T-E | Human | Esophagus | ESCC | 6.46e-07 | 2.33e-01 | 0.0875 |
| 10208 | USPL1 | P2T-E | Human | Esophagus | ESCC | 4.83e-18 | 3.52e-01 | 0.1177 |
| 10208 | USPL1 | P4T-E | Human | Esophagus | ESCC | 7.71e-09 | 2.22e-01 | 0.1323 |
| 10208 | USPL1 | P5T-E | Human | Esophagus | ESCC | 2.33e-06 | 1.46e-01 | 0.1327 |
| 10208 | USPL1 | P8T-E | Human | Esophagus | ESCC | 5.48e-15 | 1.86e-01 | 0.0889 |
| 10208 | USPL1 | P9T-E | Human | Esophagus | ESCC | 1.72e-07 | 1.05e-01 | 0.1131 |
| 10208 | USPL1 | P10T-E | Human | Esophagus | ESCC | 6.47e-19 | 3.00e-01 | 0.116 |
| 10208 | USPL1 | P11T-E | Human | Esophagus | ESCC | 2.14e-06 | 4.09e-01 | 0.1426 |
| 10208 | USPL1 | P12T-E | Human | Esophagus | ESCC | 5.07e-14 | 3.32e-01 | 0.1122 |
| 10208 | USPL1 | P15T-E | Human | Esophagus | ESCC | 1.33e-08 | 1.64e-01 | 0.1149 |
| 10208 | USPL1 | P16T-E | Human | Esophagus | ESCC | 5.42e-14 | 2.28e-01 | 0.1153 |
| 10208 | USPL1 | P17T-E | Human | Esophagus | ESCC | 2.18e-05 | 1.46e-01 | 0.1278 |
| 10208 | USPL1 | P20T-E | Human | Esophagus | ESCC | 2.96e-16 | 1.39e-01 | 0.1124 |
| 10208 | USPL1 | P21T-E | Human | Esophagus | ESCC | 3.03e-05 | 8.93e-02 | 0.1617 |
| 10208 | USPL1 | P22T-E | Human | Esophagus | ESCC | 2.34e-08 | 2.65e-01 | 0.1236 |
| 10208 | USPL1 | P23T-E | Human | Esophagus | ESCC | 3.81e-07 | 7.42e-02 | 0.108 |
| 10208 | USPL1 | P24T-E | Human | Esophagus | ESCC | 2.11e-02 | 6.48e-02 | 0.1287 |
| 10208 | USPL1 | P26T-E | Human | Esophagus | ESCC | 5.77e-13 | 2.15e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:000699713 | Esophagus | ESCC | nucleus organization | 96/8552 | 133/18723 | 4.66e-10 | 1.21e-08 | 96 |
| GO:00987812 | Esophagus | ESCC | ncRNA transcription | 45/8552 | 56/18723 | 1.05e-07 | 1.72e-06 | 45 |
| GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
| GO:00093011 | Esophagus | ESCC | snRNA transcription | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:00069974 | Oral cavity | OSCC | nucleus organization | 85/7305 | 133/18723 | 5.12e-09 | 1.12e-07 | 85 |
| GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
| GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
| GO:0009301 | Oral cavity | OSCC | snRNA transcription | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
| GO:001820521 | Oral cavity | EOLP | peptidyl-lysine modification | 72/2218 | 376/18723 | 2.38e-05 | 3.56e-04 | 72 |
| GO:007064611 | Oral cavity | EOLP | protein modification by small protein removal | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
| GO:000699721 | Oral cavity | EOLP | nucleus organization | 29/2218 | 133/18723 | 7.82e-04 | 6.24e-03 | 29 |
| GO:0030575 | Oral cavity | EOLP | nuclear body organization | 6/2218 | 16/18723 | 7.66e-03 | 3.66e-02 | 6 |
| GO:001820531 | Oral cavity | NEOLP | peptidyl-lysine modification | 64/2005 | 376/18723 | 1.21e-04 | 1.43e-03 | 64 |
| GO:00069973 | Oral cavity | NEOLP | nucleus organization | 27/2005 | 133/18723 | 7.89e-04 | 6.27e-03 | 27 |
| GO:00305751 | Oral cavity | NEOLP | nuclear body organization | 6/2005 | 16/18723 | 4.64e-03 | 2.56e-02 | 6 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| USPL1 | SNV | Missense_Mutation | c.2994N>T | p.Met998Ile | p.M998I | Q5W0Q7 | protein_coding | deleterious(0.01) | benign(0.328) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| USPL1 | SNV | Missense_Mutation | c.671N>A | p.Ala224Asp | p.A224D | Q5W0Q7 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| USPL1 | SNV | Missense_Mutation | c.272N>A | p.Ser91Tyr | p.S91Y | Q5W0Q7 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| USPL1 | SNV | Missense_Mutation | rs756082560 | c.1183N>T | p.Gly395Cys | p.G395C | Q5W0Q7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| USPL1 | SNV | Missense_Mutation | c.2851N>A | p.Glu951Lys | p.E951K | Q5W0Q7 | protein_coding | tolerated(1) | benign(0) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| USPL1 | SNV | Missense_Mutation | c.484N>A | p.Pro162Thr | p.P162T | Q5W0Q7 | protein_coding | tolerated(0.1) | possibly_damaging(0.755) | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| USPL1 | SNV | Missense_Mutation | c.1954N>G | p.Ile652Val | p.I652V | Q5W0Q7 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| USPL1 | SNV | Missense_Mutation | novel | c.2621C>T | p.Ser874Leu | p.S874L | Q5W0Q7 | protein_coding | tolerated(0.09) | benign(0.118) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| USPL1 | SNV | Missense_Mutation | novel | c.3122C>G | p.Ser1041Cys | p.S1041C | Q5W0Q7 | protein_coding | deleterious(0.01) | probably_damaging(0.912) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| USPL1 | insertion | Nonsense_Mutation | novel | c.3181_3182insACTGATTTACAACCTTCAGTTAAAGGGGTAAATAATTTTGGTGGC | p.Ile1061delinsAsnTerPheThrThrPheSerTerArgGlyLysTerPheTrpTrpLeu | p.I1061delinsN*FTTFS*RGK*FWWL | Q5W0Q7 | protein_coding | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |